Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
James K GodfreyLei GaoGeoffrey ShouseJoo Y SongStacy PakBrian LeeBihong T ChenAvyakta KallamJohn H BairdGuido MarcucciLucy Y GhodaStephanie VauleonAlexey V DanilovAlex F HerreraLarry W KwakL Elizabeth Elizabeth BuddePublished in: Blood (2024)
Although CD20xCD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces responses in CNS lymphoma.